Endometrial thickness measurement throughout a menstrual cycle in non-obese infertile patients with polycystic ovary syndrome

2012 ◽  
Vol 286 (6) ◽  
pp. 1597-1600 ◽  
Author(s):  
Ozlem Gun Eryilmaz ◽  
Esma Sarikaya ◽  
Cavidan Gulerman ◽  
Serra Akar ◽  
Nedim Cicek
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Thickness Measurement ◽  
Ovary Syndrome ◽  
Infertile Patients

scholarly journals Clomiphene Citrate versus Letrozole for Induction of Ovulation in Infertile women having Polycystic Ovarian Syndrome (Randomized Controlled Trial)

2021 ◽  
Vol 4 (7) ◽  
pp. 01-09
Author(s):  
Abdel Rahman Mohammed Saleh ◽  
Mahmoud Youssef Ali Ahmed Abdalla ◽  
Nourhan Adel Abu Elfotouh Tantawy
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Congenital Adrenal Hyperplasia ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
P Value ◽  
Adrenal Hyperplasia ◽  
Ovary Syndrome ◽  
Infertile Women

Background: Polycystic ovary syndrome is a disorder but with unclear etiology that its diagnosis depends on exclusion of other etiologies with ovulatory disorders and androgen excess as congenital adrenal hyperplasia, 21-hydroxylase deficient non classic congenital adrenal hyperplasia (NCAH), adrenal or ovarian androgen-secreting tumors, disorders of adrenocortical dysfunction as Cushing’s disease, and abuse of androgenic or anabolic drugs. Polycystic ovary syndrome affects approximately 6-15% of women in reproductive age and constitutes 50% of the causes of infertility in women. Aim of the Work: To compare the efficacy of letrozole on ovulation induction to that of clomiphene citrate in women suffering polycystic ovary syndrome and the effect on the follicular maturation, endometrial thickness and pregnancy rate. This study was carried in the outpatient infertility clinic of Ain-Shams Maternity Hospital during the period from November 2020 till April 2021. Patients and Methods: This study included 80 infertile women diagnosed as having polycystic ovary syndrome. Women were randomized into two groups. Letrozole group (1) included 40 women who were given the aromatase inhibitor (Letrozole) orally in a 5mg dose daily from day 3 to day 7 of the menstrual cycle. While Clomiphene citrate group (2) included 40 women who were given the clomiphene citrate orally in 100mg dose daily from day 3 to day 7 of the menstrual cycle. All women were counseled and informed consent was obtained before recruitment. Results: In this study, ovulation rate was significantly more frequent in the Letrozole group (82.5%, 33 women reached ovulation successfully) than in Clomiphene citrate group (60%, 24 women reached ovulation successfully) within P value=0.024. Clomiphene citrate at a dose of 100mg showed more efficacies in the number of follicle ≥18mm than Letrozole at a dose of 5mg. In Letrozole group, the number of follicles (≥18mm in diameter) ranged from 1 to 2 with a Mean±SD= 1.4±0.65 and in Clomiphene citrate group, the number of follicles (≥18mm in diameter) ranged from 1 to 3 with a Mean±SD= 1.9± 0.41 (P value=0.0001). Conclusion: Letrozole can be considered as a first line treatment of anovulation in polycystic ovary syndrome. But, moreover studies including larger number of cases will further confirm the efficacy of letrozole versus clomiphene citrate in induction of ovulation, reaching to the optimum doses for aromatases inhibitors, more observation on endometrial thickness, incidence of pregnancy outcomes, incidence of abortion and incidence of congenital fetal malformations.

scholarly journals Using Of Human Menopausal Gonadotropin Hormone Versus Oral Ovarian Stimulation Agents In Induction Of Ovulation In Women With Polycystic Ovary Syndrome In Salah Al-Deen Hospital/Tikrit City

2020 ◽  
Vol 04 (2) ◽  
pp. 13-25
Author(s):  
Haifaa Ajaj ◽  
Musryia Hassein
Keyword(s):  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Controlled Clinical Trial ◽  
Human Menopausal Gonadotropin ◽  
Therapeutic Effects ◽  
Ovary Syndrome ◽  
Significant Difference ◽  
Cycle Group

Polycystic ovary syndrome is a common cause of an ovulatory infertility. Drugs like Aromatase inhibitors, Human menopausal gonadotropin, used for ovulation induction. The aim of this study was carried out to compare the therapeutic effects of gonadotropin hormone versus oral ovarian stimulating agents. A prospective randomized controlled clinical trial was carried out in the Salahdeen general hospital in Tikrit from 1st Feb-30th August 2020. About 75 PCOs patients enrolled randomly in the study and divided equally into 3 groups as below: Group A treated with (75 IU intramuscular HMG gonadotropin) daily for 5 days starting Day 2 of menstrual cycle. Group B treated with oral clomiphene citrate 100 mg daily for 5 days starting Day 2 of menstrual cycle. Group C treated with oral Letrezole 5 mg daily for 5 days starting Day 2 of menstrual cycle. Multiple mature follicles were obtained commonly by HMG, followed by Letrozole, then Clomiphene, this relation was statistically significant. Endometrial thickness was higher among those treated with HMG (10.5±1.7) than those treated by Clomiphene (9.03±0.9), and then treated by letrozole (8.5±1.2). This is a significant difference in ET value between Clomiphene, letrozole, and HMG. Chemical pregnancy (early pregnancy loss that occurs shortly after implantation may account to 50-75% of all miscarriages) was higher among those treated with HMG (20%), while it was (16%) of those treated with Clomiphene, and (12%) of the Letrozole group, this relation was statistically not significant. In conclusion, HMG had the highest response rate, followed by Letrozole, and Clomiphene. The multiple mature follicles was obtained commonly by HMG, followed by Letrozole, then Clomiphene.

scholarly journals Comparison of Pregnancy Rate in Patients With Polycystic Ovary Syndrome Treated With Clomiphene Alone and in Combination With N-acetyl Cysteine: A Randomized Clinical Trial

2018 ◽  
Vol 7 (2) ◽  
pp. 185-189 ◽  
Author(s):  
Nayereh Ghomian ◽  
Nayereh Khadem ◽  
Somayeh Moeindarbari ◽  
Aghdas Abdolrazagh
Keyword(s):  
Clinical Trial ◽  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Pregnancy Rate ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Ovary Syndrome ◽  
The Third ◽  
The Mean ◽  
And Control

Objectives: Polycystic ovary syndrome (PCOS) is one of the frequent endocrine disorders among young females, which can cause infertility. Recently, evidence has shown the beneficial impacts of N-acetyl cysteine (NAC) use along with clomiphene citrate on the treatment of infertility caused by PCOS. Regarding this, the present study aimed to compare the pregnancy rate between the PCOS patients treated with clomiphene and those received clomiphene along with NAC. Materials and Methods: This blinded randomized controlled clinical trial was performed on 66 patients with PCOS who presented with infertility at Milad Infertility Center in Mashhad, Iran, in 2015. The patients were divided into two groups of intervention and control using a random number table. In the intervention group, 100 mg of clomiphene (i.e. two pills) along with 1200 mg of NAC (i.e. two 600 mg pills) were given to the participants from the third day of the menstrual cycle for five days. In the control group, 100 mg of clomiphene was administered from the third day of the cycle for 5 days. The patients’ response to medications as well as the number and size of follicles were assessed using the vaginal ultrasound. Results: The 2 study groups had no significant difference regarding age, duration of infertility, body mass index, history of infertility treatment, and endometrial thickness on the third day of the menstrual cycle. The mean endometrial thickness was 7.47±1.6 (NAC/ clomiphene) and 7.58±2.1 mm (clomiphene) on the 12th day of the menstrual cycle (P=0.810). Furthermore, the mean sizes of the follicles were 13.6±4.2 (clomiphene) and 15.9±5.1 mm (NAC/clomiphene) (P=0.301). The mean numbers of follicles were 1.56±0.9 (clomiphene) and 1.8±0.9 (NAC/clomiphene) (P=0.069). In total, 7 (21.2%) and 5 (15.1%) patients in the intervention and control groups had a positive beta-hCG result, respectively (P=0.260). Conclusions: As the findings of this study revealed, the addition of NAC to clomiphene treatment was not associated with an increased chance of pregnancy in patients with PCOS-related infertility.

scholarly journals Endometrial Thickness as a Predictor of Endometrial Hyperplasia in Infertile Patients with Polycystic Ovary Syndrome

2018 ◽  
Vol 08 (02) ◽  
pp. 92-104
Author(s):  
Moamar Al-Jefout ◽  
Aiman Al-Qtaitat ◽  
Dhamia Al-Rahal ◽  
Nedal Al-Nawaiseh ◽  
Futoon Rawashdeh
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Endometrial Hyperplasia ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Ovary Syndrome ◽  
Infertile Patients

scholarly journals Thyroxine Supplementation May Improve Ovulation and Pregnancy Rates in Infertile Patients with Polycystic Ovary Syndrome and Subclinical Hypothyroidism

2019 ◽  
Vol 3 (2) ◽  
pp. 01-05
Author(s):  
Hesham Ammar
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Subclinical Hypothyroidism ◽  
Ovulation Induction ◽  
Prospective Observational Study ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Clomiphene Citrate ◽  
Pregnancy Rates ◽  
Ovary Syndrome ◽  
Infertile Patients

This prospective observational study was conducted on 220 patients with polycystic ovary syndrome (PCOS) and subclinical hypothyroidism (SCH) who were allocated into two groups; group one (n=112) received clomiphene citrate (CC) plus thyroxine while group two received only CC for ovulation induction. Patients receiving CC and thyroxine exhibited higher ovulation rate (p<0.001), higher endometrial thickness (p<0.05), higher number of dominant follicles (p<0.001) and higher pregnancy rate (p<0.001) compared to their counterparts receiving only CC. Thyroxine supplementation improves ovulation and pregnancy rates in infertile patients with PCOS and SCH receiving CC for ovulation induction who are therapy naïve.

Prevalence of polycystic ovary syndrome in infertile patients in Albania

2013 ◽  
Author(s):  
Mimoza Dollenga ◽  
Thanas Fureraj ◽  
Kosta Dhima ◽  
Edmond Bizbiqi ◽  
Artan Simaku
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome ◽  
Infertile Patients

EFFECT OF AROMATASE INIBITOR IN OVULATION INDUCTION IN FETILE WOMEN WITH POLYCYSTIC OVARY SYNDROME

2014 ◽  
pp. 86-93
Author(s):  
Minh Tam Le
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Ovulation Induction ◽  
Polycystic Ovary ◽  
Endometrial Thickness ◽  
Statistical Significance ◽  
Ovulation Rate ◽  
Normal Body Mass Index ◽  
Ovary Syndrome ◽  
Group I ◽  
First Choice

Backgrounds: Polycystic Ovary Syndrome (PCOS) is one of the most common causes of female infertility due to ovulation disorders. Clomiphene citrate (CC) is a first choice to restore ovulation but it has some side effects by estrogen receptor down-regulation. Aromatase inhibitor (AI) is a newer class of drugs which increases the production of endogenous FSH to stimulate ovulation. Subjects and methods: randomized control trial to compare 64 cases of infertile women with PCOS examined at the Hue University Hospital, alternately used AI (group I) or CC (group II) for ovulation induction from day 2 cycle. Follow-up follicle growth, endometrium and ovulation via ultrasound. Evaluation were done on 10th day cycle, day of hCG trigger and after administration of hCG. Results: Total of 64 PCOS cases distributed into 2 groups using alternatively AI and CC had similar characteristics with average age of 28.8 ± 4.6, the majority were primary infertility (84.4%), infertility duration was 2.6 ± 2.4 years, 85.9% had oligomenorrhrea or amenorrhea, normal body mass index accounts for 60.9% and 21.9% was lean. Evaluation of both groups on day 10 revealed no differences in the dominant follicle and endometrial thickness. Number of days until the follicle mature appears to be shorter in AI group (15.1 ± 2.9) compared to the CC group (16.5 ± 2.8) with statistical significance. The number of mature follicles in 2 groups were not different at a rate of 81.3% (AI) and 84.4% (CC) but a higher proportion of single mature follicle in the AI ​​group (71.9%) compared with the CC group (65.7%) and There is no case with 3-4 mature follicles in the AI group. The rate of thin endometrium (<8 mm) in the AI group (25%) was lower than the CC group (53.1%) with statistically significance and higher ovulation rate (68.8%) compared with the CC group (56.3%) but have not found statistically significant. Conclusion: Two drugs AI and CC potentially induce follicle development and ovulation similarly, but AI has the potential to be more effective than CC on factors such as the shorter stimulation duration, increasing rate of single follicle, limiting multiple pregnancies, improve endometrial thickness and higher ovulation rate. More researches are needed with a larger sample size to clarify the statistical significance of differences.

scholarly journals Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial

Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Haiqing Qian ◽  
Wenting Xu ◽  
Lijuan Cui ◽  
Rong Wang ◽  
Jiahui Wang ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Randomized Controlled Trial ◽  
Menstrual Cycle ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Controlled Trial ◽  
Close Monitoring ◽  
Ovary Syndrome ◽  
Kidney Deficiency ◽  
Randomized Controlled

Abstract Background Polycystic ovary syndrome (PCOS) is a common reproductive endocrine disease in women. Insulin resistance (IR) has emerged as a central contributor to the pathogenesis of this disease. According to traditional Chinese medicine (TCM), kidney deficiency is the main syndrome of PCOS. The deficiency of the kidney cannot vaporize water-dampness, and the retention of water-dampness accumulates into phlegm dampness stagnation, resulting in visceral dysfunction and metabolic disorder. TCM involving syndrome differentiation and treatment is widely used to adjust women’s menstrual cycles. Our patented formula Bushen Huatan Decoction (BSHTD) has been proven to be effective in the clinical treatment of IR-PCOS. Baduanjin also plays an important role in improving metabolic syndrome through lifestyle intervention. This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS. Methods/design This is a randomized controlled trial involving 190 participants diagnosed with IR-PCOS. All participants will be randomly allocated into 5 groups: group A will receive metformin; group B, BSHTD; group C, Baduanjin; group D, BSHTD combined with metformin; and group E, BSHTD combined with Baduanjin. One course of treatment lasts 3 months, a total of two courses. The primary outcomes are changes in the homeostatic model assessment of insulin resistance (HOMA-IR) and improvements in the oral glucose tolerance test (OGTT) and insulin-releasing test (INS). The secondary outcomes are improvements in the menstrual cycle, ovulation rate, clinical pregnancy rate, basic serum sex hormone levels, free androgen index (FAI), Ferriman-Gallwey scores, body mass index (BMI) and TCM syndrome scores. The related observation indexes will be collected at baseline, during the process of treatment and at the 6-month follow-up. Simultaneously, close monitoring of possible adverse events will be performed throughout the trial process. Discussion This trial will investigate the efficacy of the comprehensive intervention program of Bushen Huatan Decoction combined with Baduanjin on the adjustment of the menstrual cycle, improvement of insulin resistance and correction of glucose metabolism disorder in IR-PCOS patients. It is expected to form an alternative treatment of TCM-behaviour intervention therapy for IR-PCOS and promote the Chinese fitness Qigong Baduanjin in the application of lifestyle diseases. Trial registration Chinese Clinical Trial Registry ChiCTR2100043415. Registered on 15 February 2021.

Sign in / Sign up

Export Citation Format

Share Document